PROTECT IV

• Research type

  Research Study

• Full title

  Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial

• IRAS ID

  320316

• Contact name

  Jonathan Hill

• Contact email

  j.hill@rbht.nhs.uk

• Sponsor organisation

  Abiomed Europe GmbH

• Clinicaltrials.gov Identifier

  NCT04763200

• Duration of Study in the UK

  1 years, 2 months, 1 days

• Research summary

  The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  23/LO/0277

• Date of REC Opinion

  26 May 2023

• REC opinion

  Further Information Favourable Opinion